{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:27:13Z","timestamp":1794378433075,"version":"4.9.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.anai.2021.09.009","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T22:01:14Z","timestamp":1632348074000},"page":"627-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Strategies for choosing a biologic for your patient with allergy or asthma"],"prefix":"10.1016","volume":"127","author":[{"given":"Tara","family":"Saco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel C.","family":"Ugalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Cardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.anai.2018.02.029","article-title":"Uses of biologics in allergic diseases: what to choose and when","volume":"120","author":"Saco","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2021.09.009_bib0003","series-title":"Murray and Nadel's Textbook of Respiratory Medicine","first-page":"713","article-title":"Asthma","author":"Woodruff","year":"2016"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0004","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jaci.2016.03.010","article-title":"Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis\u2014PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy","volume":"137","author":"Muraro","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0005","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","article-title":"Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab","volume":"141","author":"Gill","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0006","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0007","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2017.10.010","article-title":"Omalizumab response in patients with chronic idiopathic urticaria: insights from the XTEND-CIU study","volume":"78","author":"Casale","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.anai.2021.09.009_bib0008","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0009","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0010","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1945892419884774","article-title":"Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Yu","year":"2020","journal-title":"Am J Rhinol Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11882-020-0897-8","article-title":"New developments in non-allergen-specific therapy for the treatment of food allergy","volume":"20","author":"Long","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0012","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40413-018-0217-0","article-title":"Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases","volume":"11","author":"Celebi Sozener","year":"2018","journal-title":"World Allergy Organ J"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0013","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jaci.2018.11.032","article-title":"Omalizumab effectiveness in asthma-COPD overlap: post hoc analysis of Prospero","volume":"143","author":"Hanania","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2021.09.009_bib0014","unstructured":"Genentech, Inc. US Food and Drug Administration. Xolair (omalizumab). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103976s5225lbl.pdf. Accessed May 29, 2021."},{"key":"10.1016\/j.anai.2021.09.009_bib0015","unstructured":"GlaxoSmithKline, LLC. U.S. Food and Drug Administration. Nucala (mepolizumab). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761122Orig1s000Lbl.pdf. Accessed May 29, 2021."},{"issue":"13","key":"10.1016\/j.anai.2021.09.009_bib0016","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2021.09.009_bib0017","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.anai.2021.09.009_bib0018","first-page":"1","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"2600","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2021.09.009_bib0019","first-page":"e9684","article-title":"Mepolizumab as possible treatment for allergic bronchopulmonary aspergillosis: a review of eight cases","volume":"12","author":"Tolebeyan","year":"2020","journal-title":"Cureus"},{"issue":"17","key":"10.1016\/j.anai.2021.09.009_bib0020","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2021.09.009_bib0021","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0022","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a Broad Range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1164\/rccm.201707-1323OC","article-title":"Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab","volume":"197","author":"Mukherjee","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0024","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.anai.2020.08.167","article-title":"P509 reslizumab an interleukin-5 antagonist monoclonal antibody for uncontrolled chronic rhinosinusitis with nasal polyps","volume":"125","author":"Nsouli","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2021.09.009_bib0025","unstructured":"Teva Pharmaceutical Industries, Ltd, US Food and Drug Administration. Cinqair. (reslizumab). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761033lbl.pdf. Accessed June 3, 2021."},{"key":"10.1016\/j.anai.2021.09.009_bib0026","unstructured":"Sanofi Biotechnology and Regeneron Pharmaceuticals, Inc, US Food and Drug Administration. Dupixent (dupilumab). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761055s007lbl.pdf. Accessed June 13, 2021."},{"issue":"26","key":"10.1016\/j.anai.2021.09.009_bib0027","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2021.09.009_bib0028","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2021.09.009_bib0029","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2021.09.009_bib0030","unstructured":"AstraZeneca Pharmaceuticals LP, US Food and Drug Administration. Fasenra (benralizumab). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf. Accessed June 13, 2021."},{"issue":"10056","key":"10.1016\/j.anai.2021.09.009_bib0031","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.anai.2021.09.009_bib0032","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of Benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (Sirocco): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.anai.2021.09.009_bib0033","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2021.09.009_bib0034","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1080\/02770903.2016.1178281","article-title":"Omalizumab treatment in asthma-COPD overlap syndrome","volume":"53","author":"Tat","year":"2016","journal-title":"J Asthma"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0035","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/08923973.2016.1173057","article-title":"Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels","volume":"38","author":"Yalcin","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"11","key":"10.1016\/j.anai.2021.09.009_bib0036","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0037","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines\u2014recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0038","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaip.2020.10.048","article-title":"How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit","volume":"9","author":"Pepper","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2021.09.009_bib0039","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.jaip.2019.01.017","article-title":"Efficacy and safety of reslizumab in patients with severe asthma with inadequate response to omalizumab: a multicenter, open-label pilot study","volume":"7","author":"P\u00e9rez de Llano","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0040","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.anai.2021.09.009_bib0041","doi-asserted-by":"crossref","first-page":"8183","DOI":"10.4049\/jimmunol.174.12.8183","article-title":"Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity","volume":"174","author":"Ying","year":"2005","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.anai.2021.09.009_bib0042","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.anai.2021.09.009_bib0043","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0044","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2021.09.009_bib0045","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1111\/all.14308","article-title":"Past, present, and future of anti-IgE biologics","volume":"75","author":"Guntern","year":"2020","journal-title":"Allergy"},{"issue":"14","key":"10.1016\/j.anai.2021.09.009_bib0046","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0047","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.jaip.2018.11.018","article-title":"Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria","volume":"7","author":"Lee","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0048","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaip.2020.11.043","article-title":"Biologics for the use in chronic spontaneous urticaria: when and which","volume":"9","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.09.009_bib0049","series-title":"Patients With Multiple Forms of Uncontrolled Chronic Urticaria (CU): Results From an Open-Label Phase 2a Study","article-title":"Efficacy and safety data of AK002, an anti-Siglec-8 monoclonal antibody","author":"Altrichter","year":"2019"},{"issue":"10209","key":"10.1016\/j.anai.2021.09.009_bib0050","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (Liberty NP SINUS-24 and Liberty NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0051","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2021.09.009_bib0052","doi-asserted-by":"crossref","unstructured":"Bagnasco D, Brussino L, Bonavia M, et\u00a0al. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis [e-pub ahead of print]. Respir Med. doi:10.1016\/j.rmed.2020.1060802020, accessed October 6, 2021.","DOI":"10.1183\/13993003.congress-2020.2264"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0053","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0054","first-page":"00306","article-title":"Indirect comparison of efficacy of dupilumab versus mepolizumab and omalizumab for severe type 2 asthma","volume":"7","author":"Pr\u00e6torius","year":"2021","journal-title":"Eur R J Open Res"},{"issue":"6","key":"10.1016\/j.anai.2021.09.009_bib0055","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0056","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0057","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0058","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0059","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0060","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0061","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Nemolizumab-JP01 Study Group. Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2021.09.009_bib0062","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jaip.2019.01.023","article-title":"Impact of omalizumab on food allergy in patients treated for asthma: a real-life study","volume":"7","author":"Fiocchi","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0063","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2011.01.051","article-title":"A phase II, randomized, doubleblind, parallel\u2011group, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy","volume":"127","author":"Sampson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0064","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jaci.2012.05.039","article-title":"Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy","volume":"130","author":"Savage","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0065","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cea.12862","article-title":"Individually dosed omalizumab: an effective treatment for severe peanut allergy","volume":"47","author":"Brandstr\u00f6m","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.anai.2021.09.009_bib0066","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaci.2015.10.005","article-title":"A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy","volume":"137","author":"Wood","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0067","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaci.2016.08.010","article-title":"Omalizumab facilitates rapid oral desensitization for peanut allergy","volume":"139","author":"MacGinnitie","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0068","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(17)30392-8","article-title":"Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial","volume":"3","author":"Andorf","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"22","key":"10.1016\/j.anai.2021.09.009_bib0069","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.anai.2021.09.009_bib0070","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00431-011-1540-4","article-title":"Omalizumab in the treatment of eosinophilic esophagitis and food allergy","volume":"170","author":"Rocha","year":"2011","journal-title":"Eur J Pediatr"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0071","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a Phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"17","key":"10.1016\/j.anai.2021.09.009_bib0072","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0073","doi-asserted-by":"crossref","first-page":"AB196","DOI":"10.1016\/j.jaci.2017.12.622","article-title":"Benralizumab (anti-IL5R\u03b1) depletes gut tissue eosinophilia and improves symptoms in hypereosinophilic syndrome with gastrointestinal involvement","volume":"141","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.09.009_bib0074","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2011.07.044","article-title":"An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis","volume":"141","author":"Assa'ad","year":"2011","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.anai.2021.09.009_bib0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0076","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2011.11.044","article-title":"Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial","volume":"129","author":"Spergel","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.09.009_bib0077","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2014.07.049","article-title":"Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis","volume":"135","author":"Rothenberg","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.09.009_bib0078","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.gastro.2018.10.051","article-title":"RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis","volume":"156","author":"Hirano","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621010358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621010358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:27:18Z","timestamp":1761053238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621010358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1081120621010358"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.09.009","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for choosing a biologic for your patient with allergy or asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}